Medicaid Rebates For Brands Could Rise $3.2Bn Over Next Decade Under New Law
Provision included in appropriations legislation directs manufacturers to calculate average prices for brands without including the cost of authorized generics, which will lead to higher rebates.
You may also be interested in...
Senate Finance Committee's drug pricing bill would also exclude authorized generics from calculation of average manufacturer prices and rebates and authorize installment-type payments for curative gene therapies.
The bigger 'Donut Hole' discount is a rare loss for pharma on Capitol Hill – one that may in part be because industry did too good a job fighting off a different drug pricing measure.
Results from the US Food and Drug Administration’s RCT DUPLICATE demonstration are in. The findings both legitimize certain real-world evidence studies and also highlight the challenges involved in using RWE to replicate randomized clinical trials.